Swedish Consensus Group 2011: Treatment of HCV in Adults and Children

Martin Lagging



Outline

- Guidelines from 2011
- Current therapy in Sweden
- New guidelines likely in 2014

Swedish Guidelines from 2011

Published in Scandinavian Journal of Infectious Diseases 2012

- Acute HCV infection:
 - Symptomatic: treat if not spontaneously resolved within 3 months
 - Asymptomatic: treat immediately

- Acute HCV infection:
 - Symptomatic: treat if not spontaneously resolved within 3 months
 - Asymptomatic: treat immediately
- Chronic HCV genotype 1: fibrosis stage 3-4 (FibroScan or biopsy)

- Acute HCV infection:
 - Symptomatic: treat if not spontaneously resolved within 3 months
 - Asymptomatic: treat immediately
- Chronic HCV genotype 1: fibrosis stage 3-4 (FibroScan or biopsy)
- Chronic HCV genotype 2/3: wider indications

- Acute HCV infection:
 - Symptomatic: treat if not spontaneously resolved within 3 months
 - Asymptomatic: treat immediately
- Chronic HCV genotype 1: fibrosis stage 3-4 (FibroScan or biopsy)
- Chronic HCV genotype 2/3: wider indications
- Goal: To prevent HCV complications, e.g. HCC and decompensated cirrhosis

Treatment HCV genotype 1

- Peg-Interferon + ribavirin + protease inhibitor (PI)
 - Telaprevir first-line choice because of shorter exposure to PI

Treatment HCV genotype 1

- Peg-Interferon + ribavirin + protease inhibitor (PI)
 - Telaprevir first-line choice because of shorter exposure to PI
- Duration:
 - 24-28 weeks if HCV RNA undetectable 4 weeks after addition of PI
 - 48 weeks if HCV RNA detectable 4 weeks or later timepoint after addition of PI
- If cirrhosis, 48 weeks duration

Treatment HCV genotype 2/3

Peg-Interferon + ribavirin ≥ 11 mg/kg/day

Treatment HCV genotype 2/3

- Peg-Interferon + ribavirin ≥ 11 mg/kg/day
- Duration:
 - 12-16 weeks if:
 - HCV RNA < 1000 IU/mL day 7
 - or RVR + favorable factors (age <40, mild fibrosis, or low viral load)
 - 24 weeks if RVR + unfavorable factors
 - 36-48 weeks if HCV RNA >50 IU/mL week 4 or detectable week
 12
 - 48 weeks if cirrhosis

HCV Treatment in Children

Same as in adults

• Exception: No reports on PI use in this population


Current therapy in Sweden

Current HCV Therapy

- Only cirrhotic patients are currently initiating therapy
- Considerable warehousing of patients

New Guidelines Likely in 2014

HCV and potential therapy



New DAAs likely to be approved 2013-2014 in EU

- Sofosbuvir: Polymerase Inhibitor (Gilead)
- Simeprevir: 2nd generation Protease Inhibitor (Janssen/Medivir)

Possible Interferon-free HCV Therapy from 2014

- Genotype 1
 - Simeprevir + Sofosbuvir + (ribavirin) 12 weeks

Possible Interferon-free HCV Therapy from 2014

- Genotype 1
 - Simeprevir + Sofosbuvir + (ribavirin) 12 weeks
- Genotype 2:
 - Non-cirrhotics: Sofosbuvir + ribavirin 12 weeks
 - Cirrhotics: Sofosbuvir + ribavirin ≥16 weeks

Possible Interferon-free HCV Therapy from 2014

- Genotype 1
 - Simeprevir + Sofosbuvir + (ribavirin) 12 weeks
- Genotype 2:
 - Non-cirrhotics: Sofosbuvir + ribavirin 12 weeks
 - Cirrhotics: Sofosbuvir + ribavirin ≥16 weeks
- Genotype 3:
 - Sofosbuvir + ribavirin 24 weeks (lower SVR than genotype 1 or 2)
 - The new "<u>Difficult-to-Cure</u>" genotype

Possible Interferon-free HCV Therapy from 2015-16

- Abbvie combination
- BMS combination including Daclatasvir (NS5a inhibitor)
- Gilead combination
- MSD combination
- Janssen combination?

New Issues

- Cost
 - If low:
 - Broad use likely
 - Eradication programs possible
 - If high: Only fibrosis stage 3-4 treated?

New Issues

- Cost
 - If low:
 - Broad use likely
 - Eradication programs possible
 - If high: Only fibrosis stage 3-4 treated?
- Adherence

Side-effects no longer an issue

Please Do Not Forget

- All patents expire
 - DAA patents expire 2025-2029
- Eradication programs eventually will be possible with regards to cost